Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 125 articles:
HTML format
Text format



Single Articles


    December 2017
  1. KAPADIA SN, Jeng PJ, Schackman BR, Bao Y, et al
    State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals.
    Clin Infect Dis. 2017 Dec 1. pii: 4682615. doi: 10.1093/cid/cix1062.
    PubMed     Text format     Abstract available


    November 2017
  2. BOEREKAMPS A, Newsum AM, Smit C, Arends JE, et al
    High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands.
    Clin Infect Dis. 2017 Nov 23. pii: 4654728. doi: 10.1093/cid/cix1004.
    PubMed     Text format     Abstract available


  3. ROCKSTROH JK
    Is HCV elimination in well-defined patient groups possible?
    Clin Infect Dis. 2017 Nov 23. pii: 4654730. doi: 10.1093/cid/cix1010.
    PubMed     Text format    


  4. BOEREKAMPS A, Van den Berk GE, Fanny LN, Leyten EM, et al
    Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
    Clin Infect Dis. 2017 Nov 23. pii: 4654729. doi: 10.1093/cid/cix1007.
    PubMed     Text format     Abstract available


  5. BEDIMO RJ, Adams-Huet B, Poindexter J, Brown G, et al
    The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.
    Clin Infect Dis. 2017 Nov 14. doi: 10.1093/cid/cix1011.
    PubMed     Text format     Abstract available


    October 2017
  6. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  8. PARR JB, Lodge EK, Holzmayer V, Pepin J, et al
    An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.
    Clin Infect Dis. 2017 Oct 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  9. BUTT AA, Yan P, Simon TG, Abou-Samra AB, et al
    Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Clin Infect Dis. 2017;65:1006-1011.
    PubMed     Text format     Abstract available


  10. HASHEM M, Jhaveri R, Saleh DA, Sharaf SA, et al
    Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
    Clin Infect Dis. 2017;65:999-1005.
    PubMed     Text format     Abstract available


  11. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
    The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CHHATWAL J
    Hepatitis C screening: From modeling to public health policy.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format    


  13. LIU CH, Chen YS, Wang SS, Liu CJ, et al
    Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. WEINBERG EM, Reddy KR
    Let's Make a Deal: Shortening the solid organ transplant waiting time in exchange for transmitting and treating Hepatitis C infection in the era of safe and effective DAAs.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format    


    August 2017
  15. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
    The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. ABRAHAM GM, Spooner LM
    Citius Altius Fortius: The New Paradigm In The Treatment Of Chronic Hepatitis C Disease.
    Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. KOUAME GM, Boyd A, Moh R, Badje A, et al
    Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. WANG H, Wan Z, Xu R, Guan Y, et al
    A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
    Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. LO RE V 3RD
    Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format    


  21. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
    Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  22. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
    Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
    Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. POWDERLY WG, Naggie S, Kim AY, Vargas HE, et al
    IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format    


    June 2017
  24. CHI H, Wong D, Peng J, Cao J, et al
    Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
    Clin Infect Dis. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  25. KIM AY
    The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.
    Clin Infect Dis. 2017 May 27. doi: 10.1093.
    PubMed     Text format    


  26. FELD JJ, Ramji A, Shafran SD, Willems B, et al
    Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clin Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
    How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  28. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
    Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  29. MOON J, Hyland RH, Zhang F, Brainard DM, et al
    Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
    Clin Infect Dis. 2017 May 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  30. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
    Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
    Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. OZARAS R, Balkan II, Yemisen M, Mete B, et al
    Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  32. BUTT AA, Yan P, Chew KW, Currier J, et al
    Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. TIEN PC
    HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  34. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
    Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Clin Infect Dis. 2017;64:860-869.
    PubMed     Text format     Abstract available


  36. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
    Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
    Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  37. WYLES D, Brau N, Kottilil S, Daar ES, et al
    Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
    Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
    Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
    Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
    Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  41. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. ANDERSON ES, Galbraith JW, Deering LJ, Pfeil SK, et al
    Continuum of Care for HCV Among Patients Diagnosed in the Emergency Department Setting.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  43. LO RE V
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2017;64:498-500.
    PubMed     Text format    


  44. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017;64:490-497.
    PubMed     Text format    


  45. BLOCK TM, Locarnini S, McMahon BJ, Rehermann B, et al
    Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  46. YOUNG J, Rossi C, Gill J, Walmsley S, et al
    Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  47. BHATTACHARYA D, Belperio PS, Shahoumian TA, Loomis TP, et al
    Effectiveness of All-Oral Antiviral Regimens in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  48. BURTON MJ, Naggie S
    Real World Effectiveness of DAA Therapies in HIV/HCV Co-Infection: 996 Veterans Can't Be Wrong.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  49. BEGUELIN C, Friolet N, Moradpour D, Sahli R, et al
    Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  50. ANDREONI M, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  51. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin-18 in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Coinfection Versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


    January 2017
  52. RIVERO-JUAREZ A, Frias M, Lopez-Lopez P, Risalde ML, et al
    Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection?
    Clin Infect Dis. 2017 Jan 11. pii: cix004. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  53. MASSIMO A, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2016 Dec 22. pii: ciw846. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. LO RE V 3RD
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  55. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  56. FORD MM, Johnson N, Desai P, Rude E, et al
    From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  57. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  58. LIEVELD FI, Arends JE, Amelung L, Dijk E, et al
    Overcoming Outpatient Loss to Follow-up as a Barrier to Efficiently Instituting Hepatitis B Liver-related Care.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  59. FOSTER AL, Gaisa MM, Hijdra RM, Turner SS, et al
    Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2016 Nov 9. pii: ciw740. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. BAROCAS JA, Linas BP
    Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    October 2016
  61. SARRAZIN C, Isakov V, Svarovskaia E, Hedskog C, et al
    Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  62. NAGGIE S, Holland D, Sulkowski MS, Thomas DL, et al
    HCV post-exposure prophylaxis in the healthcare worker: Why DAAs don't change a thing.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  63. MOORE MS, Ivanina E, Bornschlegel K, Qiao B, et al
    Hepatocellular Carcinoma and Viral Hepatitis in New York City.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  64. GREBELY J, Dore GJ, Zeuzem S, Aspinall RJ, et al
    Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  65. GREBELY J, Mauss S, Brown A, Bronowicki JP, et al
    Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  66. INGILIZ P, Christensen S, Kimhofer T, Hueppe D, et al
    Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals - Results from the German hepatitis C cohort (GECCO-01).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  67. KLEVENS RM, Canary L, Huang X, Denniston MM, et al
    The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  68. KLEIN MB, Althoff KN, Jing Y, Lau B, et al
    Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  69. ABRAVANEL F, Metivier S, Chauveau M, Peron JM, et al
    Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  70. KAMSTRA R, Azoulay L, Steele R, Klein MB, et al
    Hospitalizations in immigrants and non-immigrants diagnosed with chronic hepatitis C infection in Quebec.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  71. SPRADLING PR, Xing J, Rupp LB, Moorman AC, et al
    Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  72. MCMAHON BJ
    Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  73. SULKOWSKI MS, Chuang WL, Kao JH, Yang JC, et al
    No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  74. YOUNOSSI ZM, Stepanova M, Sulkowski M, Foster GR, et al
    Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and 3 Clinical Trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available



  75. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  76. WYLES DL, Sulkowski MS, Dieterich D
    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Clin Infect Dis. 2016;63 Suppl 1:S3-S11.
    PubMed     Text format     Abstract available


  77. MACBRAYNE CE, Kiser JJ
    Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016;63 Suppl 1:S12-23.
    PubMed     Text format     Abstract available


  78. ROWAN SE, Rogers M, Bayer J, Smith L, et al
    Treatment of HCV in HIV coinfected individuals in real world clinical settings: results from two large HIV care clinics.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  79. AL-KINDI SG, Zidar DA, McComsey GA, Longenecker CT, et al
    Gender differences in statin prescription rate among patients living with HIV and HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    June 2016
  80. FEDELI U, Schievano E
    Mortality waves related to Hepatitis C virus infection: multiple causes of death data from the US and Northern Italy compared.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  81. FELD JJ, Maan R, Zeuzem S, Kuo A, et al
    Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  82. SOGNI P, Gilbert C, Lacombe K, Piroth L, et al
    All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  83. GJAERDE LI, Shepherd L, Jablonowska E, Lazzarin A, et al
    Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  84. HEDENSTIERNA M, Nangarhari A, Weiland O, Aleman S, et al
    Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  85. WILSON EM, Tang L, Kottilil S
    Eradication Strategies for Chronic Hepatitis B Infection.
    Clin Infect Dis. 2016;62 Suppl 4:S318-25.
    PubMed     Text format     Abstract available


  86. TRAN TT
    Hepatitis B in Pregnancy.
    Clin Infect Dis. 2016;62 Suppl 4:S314-7.
    PubMed     Text format     Abstract available


  87. GONZALEZ SA, Perrillo RP
    Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.
    Clin Infect Dis. 2016;62 Suppl 4:S306-13.
    PubMed     Text format     Abstract available


  88. WONG GL, Wong VW, Chan HL
    Virus and Host Testing to Manage Chronic Hepatitis B.
    Clin Infect Dis. 2016;62 Suppl 4:S298-305.
    PubMed     Text format     Abstract available


  89. SHANKAR H, Blanas D, Bichoupan K, Ndiaye D, et al
    A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants.
    Clin Infect Dis. 2016;62 Suppl 4:S289-97.
    PubMed     Text format     Abstract available


  90. DANDRI M, Petersen J
    Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.
    Clin Infect Dis. 2016;62 Suppl 4:S281-8.
    PubMed     Text format     Abstract available


    May 2016
  91. COOPER C, Naggie S, Saag M, Yang JC, et al
    Successful Retreatment of HCV in Patients Coinfected with HIV Who Failed 12 Weeks of Ledipasvir/Sofosbuvir.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  92. KELLY EM, Dodge JL, Sarkar M, French AL, et al
    Marijuana Use is not Associated with Progression to Advanced Liver Fibrosis in HIV/HCV Coinfected Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  93. SOLLIMA S, D'Avolio A, Cattaneo D, Micheli V, et al
    Darunavir-based antiretroviral therapy may affect the efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in HCV/HIV-1 coinfected patients.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  94. CLEMENT ME, Park LP, Navar AM, Okeke NL, et al
    Statin Utilization and Recommendations Among HIV and HCV-Infected Veterans: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  95. KANWAL F, Kramer JR, El-Serag HB, Frayne S, et al
    Race and gender differences in the use of direct acting antiviral agents for HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  96. NICOLAS D, Esteve A, Cuadros A, Campbell CN, et al
    Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  97. RAMSAY I, Gorton RL, Patel M, Workman S, et al
    Transmission of Hepatitis B core Antibody and Galactomannan Enzyme Immunoassay positivity via immunoglobulin products: a comprehensive analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  98. SHAFRAN SD
    Reply to Menard et al.
    Clin Infect Dis. 2016;62:949-50.
    PubMed     Text format    


    March 2016
  99. LUETKEMEYER AF, McDonald C, Ramgopal M, Noviello S, et al
    12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  100. RIVERO-JUAREZ A, Frias M, Rodriguez-Cano D, Cuenca-Lopez F, et al
    Isolation of Hepatitis E virus from breast milk during acute infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  101. TOSTI ME, Alfonsi V, Lacorte E, Mele A, et al
    Acute hepatitis B after the implementation of universal vaccination in Italy: results from a 22-years surveillance (1993-2014).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  102. LY KN, Hughes EM, Jiles RB, Holmberg SD, et al
    Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  103. DEL BELLO D, Cha A, Sorbera M, Bichoupan K, et al
    Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  104. HSIEH YH, Rothman RE, Laeyendecker OB, Kelen GD, et al
    Evaluation of The CDC Recommendations for HCV Testing in an Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  105. LYONS MS, Kunnathur VA, Rouster SD, Hart KW, et al
    Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  106. MARTIN NK, Thornton A, Hickman M, Sabin C, et al
    Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  107. JONAS MC, Rodriguez CV, Redd J, Sloane DA, et al
    Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  108. HARRINGTON PR, Fleischer R, Connelly SM, Lewis LL, et al
    Reply to Merli et al.
    Clin Infect Dis. 2016;62:528-9.
    PubMed     Text format    


  109. VERMEHREN J, Maasoumy B, Maan R, Cloherty G, et al
    Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  110. KUNCIO DE, Newbern EC, Johnson CC, Viner KM, et al
    Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  111. SIMMONS B, Saleem J, Hill A, Riley RD, et al
    Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  112. SAEED S, Strumpf EC, Walmsley S, Rollet-Kurhajec K, et al
    How generalizable are the results from trials of Direct Antiviral Agents to people coinfected with HIV/Hepatitis C virus in the real world?
    Clin Infect Dis. 2016 Jan 6. pii: civ1222.
    PubMed     Text format     Abstract available


  113. MARTINELLO M, Dore GJ
    HCV direct-acting antivirals in the "real world": Efficacy comparable to clinical trials.
    Clin Infect Dis. 2016 Jan 6. pii: civ1227.
    PubMed     Text format    


  114. MENARD A, Colson P, Catherine D, Isabelle R, et al
    First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: better than ever.
    Clin Infect Dis. 2016 Jan 5. pii: civ1215.
    PubMed     Text format    


  115. KHATRI A, Dutta S, Wang H, Podsadecki T, et al
    Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Clin Infect Dis. 2016 Jan 5. pii: civ1213.
    PubMed     Text format     Abstract available


  116. STOCKDALE AJ, Geretti AM
    Reply to Boyd and Lacombe.
    Clin Infect Dis. 2016;62:130-1.
    PubMed     Text format    


  117. KESHTKAR-JAHROMI M, Rassaei N, Bruno MA, Maneval ML, et al
    Photo Quiz. A 59-Year-Old Man With Multiple Liver Lesions, Rash, and Uveitis.
    Clin Infect Dis. 2016;62:82-3.
    PubMed     Text format    


    November 2015
  118. DURHAM DP, Skrip LA, Bruce RD, Vilarinho S, et al
    The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  119. DONNELLY JP, Franco R, Wang HE, Galbraith JW, et al
    Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  120. HONER ZU SIEDERDISSEN C, Maasoumy B, Marra F, Deterding K, et al
    Drug-drug interactions with novel all oral interferon free antiviral agents in a large real-world cohort.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  121. BOYD A, Lacombe K
    More long-term assessment of transient elastography is needed for HIV-HBV co-infected patients undergoing treatment with tenofovir.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  122. BALAGOPAL A, Thomas DL
    Editorial Commentary: Who is "Special" Now?
    Clin Infect Dis. 2015;61:826-8.
    PubMed     Text format    


    August 2015
  123. SIDHARTHAN S, Kohli A, Kottilil S
    Reply to Harrington et al.
    Clin Infect Dis. 2015;61:667-8.
    PubMed     Text format    


    July 2015
  124. STARK JE
    Potential for a Significant Interaction Between Clopidogrel and Dasabuvir.
    Clin Infect Dis. 2015;61:134-5.
    PubMed     Text format    


    November 2014
  125. ABRAHAM AG, Althoff KN, Jing Y, Estrella MM, et al
    End Stage Renal Disease Among HIV-Infected Adults in North America.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: